An expert workgroup has developed the first appropriate use recommendations (AURs) for real-world use of the antiamyloid donanemab (Kisunla). “The role of appropriate use recommendations are to bridge the gap between clinical trials and clinical practice,” said guideline author Gil Rabinovici, MD, with the Department of Neurology…
